Category: Argenica Therapeutics

Argenica Therapeutics (ASX:AGN) breaking new ground in stroke treatment

December 10, 2024 Off

Argenica Therapeutics (ASX:AGN) breaking new ground in stroke treatment

By MarketOpen

Argenica Therapeutics (ASX:AGN) has dosed 80% of patients in its Phase 2 trial for ARG-007, a promising stroke therapy, with no adverse safety concerns reported.

Argenica Therapeutics (ASX:AGN) breakthrough in stroke treatment shows promise in phase 2 trial

November 1, 2024 Off

Argenica Therapeutics (ASX:AGN) breakthrough in stroke treatment shows promise in phase 2 trial

By MarketOpen

Argenica Therapeutics advances its stroke treatment with ARG-007, achieving a key safety milestone in its Phase 2 trial, signalling promising potential for brain injury recovery.